Loading stock data…
INSM
$104.74+1.36 (+1.32%)
After Hours$105.18+0.44 (+0.42%)· Last close Jun 29
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Insmed Incorporated in the Healthcare sector is trading at $104.74 with a market capitalization of $20.6B. Wall Street consensus targets $197.05 (21 analysts), implying a +88.1% move over the next 12 months. The stock is currently near its 52-week low of $90.39, remaining 31.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +88.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $305.96M↑ | $263.84M↑ | $142.34M↑ | $107.42M↑ | $92.82M |
| Gross Profit | $258.54M↑ | $219.62M↑ | $112.98M↑ | $79.34M↑ | $71.55M |
| Operating Income | -$200.28M↑ | -$249.71M↑ | -$261.35M↓ | -$253.88M↓ | -$229.84M |
| Net Income | -$163.56M↑ | -$328.49M↑ | -$370.02M↓ | -$321.69M↓ | -$256.58M |
Peer Comparison
JNJUNHPFE
Fundamentals
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial l...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$20.55B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-167.94%
Volume
Today's trading volume
2.68M
Recent News
Mizuho Maintains an Outperform Rating on Insmed Incorporated (INSM)
Insmed Incorporated (NASDAQ:INSM) is among the Best Healthcare Stocks. On June 15, Mizuho lowered its price target on Insmed Incorporated (NASDAQ:INSM) to $192 from $202. It maintained an Outperform rating on the shares. The firm stated the recent selloff created a buying opportunity even though shares have fallen 29% since the company’s first-quarter report. Mizuho found […]
Nebius and CoreWeave fall after Nasdaq 100 listing
Nabius and CoreWeave surged in the lead up to their Nasdaq 100 listing, but have fallen in the to days since their inclusions.
Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock?
Kymera Therapeutics (KYMR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Should Insmed’s (INSM) NASDAQ-100 Exit and TPIP Focus Require Action From Investors?
Insmed Incorporated was removed from the NASDAQ-100 Index on 19 June 2026, even as investor focus intensified on its experimental lung drug TPIP. Analyst commentary now emphasizes TPIP’s upcoming clinical data as a potential turning point for Insmed’s rare respiratory disease portfolio and overall outlook. We’ll now examine how heightened expectations around TPIP’s upcoming data release may reshape Insmed’s existing clinical and earnings narrative. We've uncovered the 7 dividend fortresses...
Is Insmed (INSM) One of the Most Promising Healthcare Stocks After Cantor Fitzgerald’s Target Raise?
Insmed Incorporated (NASDAQ:INSM) is one of the most promising healthcare stocks according to Wall Street analysts. On June 10, Cantor Fitzgerald reaffirmed its Overweight rating on Insmed Incorporated (NASDAQ:INSM) and raised its price target from $230 to $235. The firm pointed to an upcoming data release for Insmed’s experimental lung drug TPIP as a potential […]